Questions and answers to stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use
Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn
Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) Treatment of Hodgkin's lymphoma, 15/01/2009 Withdrawn
Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E Treatment of peripheral T-cell lymphoma, 21/08/2019 Withdrawn
Annex XV - List of topiramate containing medicinal products in the European Union
Annex XV - List of topiramate containing medicinal products in the European Union
List of medicinal products under additional monitoring
List of medicinal products under additional monitoring
MSSG recommendations on shortage of Glucagon-Like Peptide-1 (GLP-1) receptor agonists
EU actions to tackle shortages of GLP-1 receptor agonists